Second Sight Medical Products Inc  

(Public, NASDAQ:EYES)   Watch this stock  
Find more results for eyes
+0.01 (0.24%)
Real-time:   12:57PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.13 - 4.31
52 week 3.17 - 14.95
Open 4.19
Vol / Avg. 125,218.00/540,355.00
Mkt cap 151.39M
P/E     -
Div/yield     -
EPS -0.58
Shares 36.04M
Beta     -
Inst. own 20%
Jul 28, 2016
Q2 2016 Second Sight Medical Products Inc Earnings Call - 4:30PM EDT - Add to calendar
Jul 28, 2016
Q2 2016 Second Sight Medical Products Inc Earnings Release - 4:00PM EDT - Add to calendar
Apr 28, 2016
Q1 2016 Second Sight Medical Products Inc Earnings Call
Apr 28, 2016
Q1 2016 Second Sight Medical Products Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -552.33% -223.66%
Operating margin -552.80% -223.99%
EBITD margin - -220.25%
Return on average assets -91.83% -56.14%
Return on average equity -128.89% -72.95%
Employees 118 -
CDP Score - -


12744 San Fernando Road, Bldg. 3
SYLMAR, CA 91342
United States - Map
+1-818-8335000 (Phone)
+1-818-8335067 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company's product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient's glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.

Officers and directors

Robert J. Greenberg M.D. Ph.D. Chairman of the Board
Age: 48
Bio & Compensation  - Reuters
Will McGuire President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Thomas B. Miller Chief Financial Officer
Age: 59
Bio & Compensation  - Reuters
Steven D. Okland Jr. Commercial Vice President, U.S. and Canada
Bio & Compensation  - Reuters
Edward David Randolph Vice President - Manufacturing
Age: 57
Bio & Compensation  - Reuters
Gregoire Cosendai Vice President - European Operations
Age: 43
Bio & Compensation  - Reuters
James K. Miller Director - Manufacturing
Bio & Compensation  - Reuters
William J. Link Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
Aaron Mendelsohn Independent Director
Age: 60
Bio & Compensation  - Reuters
Matthew Jonathan Pfeffer Independent Director
Age: 57
Bio & Compensation  - Reuters